RT Journal Article
SR Electronic
T1 COVID-19 neutralizing antibodies predict disease severity and survival
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.15.20213512
DO 10.1101/2020.10.15.20213512
A1 Wilfredo F. Garcia-Beltran
A1 Evan C. Lam
A1 Michael G. Astudillo
A1 Diane Yang
A1 Tyler E. Miller
A1 Jared Feldman
A1 Blake M. Hauser
A1 Timothy M. Caradonna
A1 Kiera L. Clayton
A1 Adam D. Nitido
A1 Mandakolathur R. Murali
A1 Galit Alter
A1 Richelle C. Charles
A1 Anand Dighe
A1 John A. Branda
A1 Jochen K. Lennerz
A1 Daniel Lingwood
A1 Aaron G. Schmidt
A1 A. John Iafrate
A1 Alejandro B. Balazs
YR 2020
UL http://medrxiv.org/content/early/2020/10/20/2020.10.15.20213512.abstract
AB COVID-19 exhibits variable symptom severity ranging from asymptomatic to life-threatening, yet the relationship between severity and the humoral immune response is poorly understood. We examined antibody responses in 113 COVID-19 patients and found that severe cases resulting in intubation or death exhibited increased inflammatory markers, lymphopenia, and high anti-RBD antibody levels. While anti-RBD IgG levels generally correlated with neutralization titer, quantitation of neutralization potency revealed that high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G, suggesting protection from reinfection by this strain. However, SARS-CoV-2 sera was unable to cross-neutralize a highly-homologous pre-emergent bat coronavirus, WIV1-CoV, that has not yet crossed the species barrier. These results highlight the importance of neutralizing humoral immunity on disease progression and the need to develop broadly protective interventions to prevent future coronavirus pandemics.Competing Interest StatementJ.A.B. has received research support from Zeus Scientific, bioMerieux, Immunetics, Alere, DiaSorin, the Bay Area Lyme Foundation (BALF), and the National Institute of Allergy and Infectious Diseases (NIAID; Award 1R21AI119457-01) for unrelated projects. J.A.B. has served as a paid consultant to T2 Biosystems, DiaSorin and Roche Diagnostics.Funding StatementWe wish to thank Nir Hacohen, PhD and Jesse D. Bloom, PhD for spike-expression plasmids, and Michael Farzan, PhD for providing ACE2-expressing 293T cells. We also give thanks to Daniel Claiborne, PhD, and Vivek Naranbhai, MD, PhD, for input on experiments and statistical analyses. K.L.C. is supported by Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship 1F32AI143480. T.M.C. and B.M.H. were supported by award Number T32GM007753 from the National Institute of General Medical Sciences. J.F. was supported by T32AI007245. A.G.S. was supported by NIH R01 AI146779 and a Massachusetts Consortium on Pathogenesis Readiness (MassCPR) grant. J.A.B. has received research support from Zeus Scientific, bioMerieux, Immunetics, Alere, DiaSorin, the Bay Area Lyme Foundation (BALF), and the National Institute of Allergy and Infectious Diseases (NIAID; Award 1R21AI119457-01) for unrelated projects. J.A.B. has served as a paid consultant to T2 Biosystems, DiaSorin and Roche Diagnostics. A.J.I. is supported by the Lambertus Family Foundation. A.B.B. is supported by the National Institutes for Drug Abuse (NIDA) Avenir New Innovator Award DP2DA040254, the MGH Transformative Scholars Program as well as funding from the Charles H. Hood Foundation. This independent research was supported by the Gilead Sciences Research Scholars Program in HIV.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of patient samples for the development and validation of SARS-CoV-2 diagnostic tests was approved by Partners Institutional Review Board (protocol 2020P000895).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study assessed the diagnostic and prognostic performance of SARS-CoV-2 serological and immunological tests and was not a clinical trial. De-identified raw data of the results of serological assays can be provided upon request.